Think Investments’s Filana Therapeutics FLNA Stock Holding History

Think Investments’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-111,661	Closed	-$4.67M	–	23
2022 Q3	$4.67M	Hold	111,661	–	–	1.43%	20
2022 Q2	$1.88M	Sell	111,661 -39,639	-26%	-$1M	0.55%	20
2022 Q1	$5.62M	Sell	151,300 -50,000	-25%	-$2.12M	1.59%	17
2021 Q4	$8.8M	Buy	+201,300	New	+$10.6M	1.67%	15

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Think Investments's FLNA Position: Q4 2022 in Review

Think Investments sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 111,661 shares — an estimated $4.67M sold.

Think Investments first reported a position in FLNA in Q4 2021 and held it in 4 quarters. The position peaked at $8.8M in Q4 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Think Investments reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Think Investments sold 111,661 Filana Therapeutics shares in Q4 2022, an estimated $4.67M.
Think Investments first reported a position in Filana Therapeutics in Q4 2021 and held it in 4 quarters.
Think Investments's Filana Therapeutics position peaked at $8.8M in Q4 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Think Investments's 13F filing for Q4 2022, filed 14 Feb 2023.